Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $17.83.
VYGR has been the subject of several recent research reports. StockNews.com lowered Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 13th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, July 31st. Wedbush decreased their price target on Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 15th.
View Our Latest Stock Report on Voyager Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics in the second quarter worth about $12,668,000. Farallon Capital Management LLC boosted its position in Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company's stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock worth $30,087,000 after purchasing an additional 702,030 shares during the period. American Century Companies Inc. grew its stake in shares of Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock worth $8,063,000 after purchasing an additional 249,659 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at approximately $1,569,000. Hedge funds and other institutional investors own 48.03% of the company's stock.
Voyager Therapeutics Trading Down 2.0 %
Voyager Therapeutics stock traded down $0.13 during midday trading on Wednesday, hitting $6.47. The stock had a trading volume of 324,760 shares, compared to its average volume of 679,376. Voyager Therapeutics has a 52-week low of $6.06 and a 52-week high of $11.72. The company has a market capitalization of $352.81 million, a PE ratio of -129.37 and a beta of 0.96. The firm's fifty day moving average is $8.21 and its two-hundred day moving average is $8.37.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the prior year, the firm posted ($0.51) EPS. As a group, equities research analysts predict that Voyager Therapeutics will post -1.47 earnings per share for the current fiscal year.
About Voyager Therapeutics
(
Get Free ReportVoyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Recommended Stories
![Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)](https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=VYGR)
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.